Edwards Lifesciences Rises 0.54% Amid FTC Lawsuit Blocking $945M JenaValve Acquisition as Stock Ranks 443rd in $0.22B Trading Volume

On August 8, 2025, Edwards Lifesciences (EW) rose 0.54% with a trading volume of $0.22 billion, ranking 443rd in market activity. The stock’s movement coincided with regulatory scrutiny over its proposed $945 million acquisition of JenaValve Technology, a key player in transcatheter aortic valve replacement (TAVR-AR) devices. The Federal Trade Commission (FTC) filed a lawsuit to block the deal, arguing it would eliminate direct competition in the U.S. market for TAVR-AR devices, stifling innovation and limiting patient access to alternatives. Edwards, which already owns rival JC Medical, contends the acquisition will accelerate treatment advancements for aortic regurgitation, a condition affecting over 8 million Americans. Despite the regulatory challenge, the company raised its 2025 adjusted earnings guidance to $2.45–$2.55 per share, citing operational efficiencies and growth in its TAVR segment.

The FTC’s action highlights growing antitrust concerns in the medical device sector. The agency emphasized that the merger would consolidate Edwards’ control over two firms conducting U.S. clinical trials for TAVR-AR devices, reducing incentives for innovation. JenaValve’s Trilogy system is positioned to enter the U.S. market soon, but the FTC warned that combined ownership of both companies would undermine the competitive dynamics driving product development. Edwards has resisted divesting JC Medical to address these concerns and plans to pursue regulatory approval by early 2026. The company’s recent guidance revisions and TAVR growth rate projections indicate confidence in maintaining market leadership despite the regulatory headwinds.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.